Xcout IntelCellect Biotechnology
Cellect Biotechnology Ltd. was an Israeli biotechnology company developing cell-selection and regenerative-medicine technologies, including its ApoGraft platform for enriching stem cells from bone marrow or other cell sources. Its products were intended primarily for clinical and research applications involving hematopoietic stem-cell transplantation and cell-based therapies.
Subscribe to see Cellect Biotechnology’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Cellect Biotechnology at a glance
Cellect Biotechnology is a biotechnology company headquartered in Israel. It has raised at least $11.3M across the 3 funding rounds on record. Its most recent funding round raised $3M in October 2020.
Cellect Biotechnology funding rounds
At least $11.3M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $3M | — | |
| SEC Form D filing | $4M | — | |
| SEC Form D filing | $4.3M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Cellect Biotechnology competitors
A few of Cellect Biotechnology's closest competitors — see the full list of competitors and alternatives →
ImmuneBridge Inc. is a biotechnology company headquartered in San Francisco, California, that develops a hematopoietic stem cell (HSC) expansion and differentiation platform.
Genetix Biotherapeutics develops and delivers one-time, curative genetic therapies for patients suffering from rare, severe genetic diseases such as sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy. The company utilizes patients' own blood stem cells, modifying them outside the body to correct underlying genetic defects and restore normal function. It serves patients, families, and healthcare providers by providing these advanced treatments alongside dedicated clinical support and research programs.
Junten Bio Co. Ltd. is a Japanese pharmaceutical and biotechnology corporation headquartered in Tokyo, specializing in the research and development of cell and regenerative medicine.
StemCyte is a global cord blood banking and regenerative therapeutics company that provides public and private umbilical cord blood and cord tissue preservation services for expectant families. The company processes, tests, and cryopreserves stem cells for family protection and clinical use, and supplies cellular materials for transplants and medical research.
StemCell Institute Inc. provides specialized stem cell banking services throughout Japan. In addition to its core preservation activities, the company is deeply involved in the research and development of medical therapies that utilize stem cells, and it also offers banking solutions for blood vessel cells. Founded in 1999, StemCell Institute Inc. is headquartered in Tokyo, Japan, and operates as a subsidiary of Trim Medical Holdings Inc.
Medipost Co., Ltd. is a South Korean biotechnology company developing and commercializing stem-cell-based regenerative medicines, including treatments derived from human umbilical cord blood mesenchymal stem cells. It also operates a cord-blood banking business serving expectant parents and families.
Get Cellect Biotechnology's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Cellect Biotechnology in Xcout Intel
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access